Iranian Companies Supplying Plasma-Derived Drugs

“The country's need to plasma-derived drugs will be significantly met by the end of the next year with these efforts,” Qaneyee said.

One of the active companies in this field has a production capacity of 300,000 liters annually and another company produces 80,000 50-ml vials of albumin and 72,000 50-ml vials of intravenous immunoglobulin, meeting 25% of the country's needs,” he added.

“Also, another company has 10 beds and 10 plasmapheresis machines for plasma collection,” Qaneyee said.

In a relevant development in December, Iranian researchers at a knowledge-based company had managed to meet the country's needs for plasma-derived medicinal products (PDMPs) .

With the support of the Innovation and Prosperity Fund of Iran and efforts of scientists at the knowledge-based company, the production capacity of blood plasma-derived products has increased and its production line has been expanded.

“Our company is the first and only blood plasma refinery in the Middle-East whose raw materials are human blood plasma from people who donate it voluntarily,” said Bardia Farzamfar, the managing director of the knowledge-based company.

“Products extracted from blood plasma are used to treat autoimmune diseases, hemophilia, or people who have lost blood for any reason and whose bodies need to compensate for the lost blood,” he added.

“The main products of our knowledge-based company are drugs like albumin and immunoglobulin (IVIG), which are used in the treatment of various diseases,” Farzamfar said.

“Our company has been producing and marketing albumin and immunoglobulin drugs for nearly three years. Recently, our company's research and development (R&D) team has also started making factor products and we are making efforts to produce and market them within the next two years,” he added.

4155/v